Compound reference
This combination brings together BPC-157, Thymogen. Explore each component’s research focus below, followed by the evidence for the combination.
BPC-157 is studied for processes involved in tendon and connective-tissue repair, including collagen organization and cellular responses to injury. The potential application is tissue recovery, supported here by preclinical findings rather than established clinical benefits.
Thymogen is investigated in immune-cell signaling and blood-cell development. These early mechanistic questions differ from demonstrated prevention of illness or recovery benefits in an animal-care formula.
Explore the selected studies, their findings and their limits.
A rat Achilles-tendon injury experiment reported improved tendon strength, functional measures and collagen organization with BPC-157 compared with controls. A separate study in rat tendon fibroblasts found increased growth-hormone receptor expression. Together, these findings explain interest in tissue-repair signaling, but neither study demonstrates healing, pain relief or safety in people or dogs.
A laboratory comparison of synthetic immune-related peptides examined blood-cell colony formation. Thymogen did not reproduce the stronger effect of the comparator peptide under the tested conditions. This illustrates why related thymic peptides are not interchangeable. Such experiments do not establish fewer infections or improved recovery in dogs.
The sources above examine individual constituents or related molecules. They do not test this exact combination. A combined effect, improved recovery or greater safety cannot be inferred by adding the individual findings together.
The studies discussed here do not establish the safety or effectiveness of this catalog formula in dogs. Rat, mouse, cell-culture and human findings are not canine clinical results; they also do not establish absorption or effects from the listed oral formula.
For more information, contact info@aurevixpeptides.com.
Editorial review: September 23, 2026
